Search

Your search keyword '"Liu, Dao-Zhou"' showing total 22 results
Start Over Author "Liu, Dao-Zhou" Search Limiters Academic (Peer-Reviewed) Journals
22 results on '"Liu, Dao-Zhou"'

15. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin

Author

Song, Yan-feng, Liu, Dao-zhou, Cheng, Ying, Teng, Zeng-hui, Cui, Han, Liu, Miao, Zhang, Bang-le, Mei, Qi-bing, and Zhou, Si-yuan

Abstract

The experiment aims to increase antitumor activity while decreasing the systemic toxicity of doxorubicin (DOX). Charge reversible and mitochondria/nucleus dual target lipid hybrid nanoparticles (LNPs) was prepared. The in vitroexperimental results indicated that LNPs released more amount of DOX in acidic environment and delivered more amount of DOX to the mitochondria and nucleus of tumor cells than did free DOX, which resulted in the reduction of mitochondrial membrane potential and the enhancement of cytotoxicity of LNPs on tumor cells. Furthermore, the in vivoexperimental results indicated that LNPs delivered more DOX to tumor tissue and significantly prolonged the retention time of DOX in tumor tissue as compared with free DOX, which consequently resulted in the high antitumor activity and low systemic toxicity of LNPs on tumor-bearing nude mice. The above results indicated that charge reversible mitochondria/nucleus dual targeted lipid hybrid nanoparticles greatly enhanced therapeutic efficacy of DOX for treating lung cancer.

Published
2024
Full Text
View/download PDF

21. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin.

Author

Song YF, Liu DZ, Cheng Y, Teng ZH, Cui H, Liu M, Zhang BL, Mei QB, and Zhou SY

Subjects
Animals, Cell Line, Tumor, Female, Humans, Hydrogen-Ion Concentration, Lipids chemistry, Male, Membrane Potential, Mitochondrial drug effects, Mice, Mice, Nude, Nanoparticles chemistry, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, Xenograft Model Antitumor Assays, Antibiotics, Antineoplastic administration & dosage, Cell Nucleus drug effects, Doxorubicin administration & dosage, Drug Carriers chemistry, Mitochondria drug effects, Neoplasms drug therapy
Abstract

The experiment aims to increase antitumor activity while decreasing the systemic toxicity of doxorubicin (DOX). Charge reversible and mitochondria/nucleus dual target lipid hybrid nanoparticles (LNPs) was prepared. The in vitro experimental results indicated that LNPs released more amount of DOX in acidic environment and delivered more amount of DOX to the mitochondria and nucleus of tumor cells than did free DOX, which resulted in the reduction of mitochondrial membrane potential and the enhancement of cytotoxicity of LNPs on tumor cells. Furthermore, the in vivo experimental results indicated that LNPs delivered more DOX to tumor tissue and significantly prolonged the retention time of DOX in tumor tissue as compared with free DOX, which consequently resulted in the high antitumor activity and low systemic toxicity of LNPs on tumor-bearing nude mice. The above results indicated that charge reversible mitochondria/nucleus dual targeted lipid hybrid nanoparticles greatly enhanced therapeutic efficacy of DOX for treating lung cancer.

Published
2018
Full Text
View/download PDF

22. Investigational selective melatoninergic ligands for receptor subtype MT2.

Author

Wan N, Zhang FF, Ju J, Liu DZ, Zhou SY, and Zhang BL

Subjects
Animals, Dose-Response Relationship, Drug, Humans, Ligands, Melatonin chemistry, Molecular Structure, Structure-Activity Relationship, Melatonin metabolism, Melatonin pharmacology, Receptor, Melatonin, MT2 antagonists & inhibitors, Receptor, Melatonin, MT2 metabolism
Abstract

Melatonin, an endogenous ligand for melatonin receptor, plays an important role in modulating various physiological activities through acting on different subtypes MT1, MT2 or the binding site MT3. The distinct roles of the receptor subtypes provide great potential for receptor-specific pharmacological agents. Melatonin has no subtypeselectivity, so it is very important to develop different subtype-selective ligand for receptor subtype research and drug development. In order to provide guidance for developing high selective ligand, this paper focused on the MT2-selective ligands, which developed well in the past years. The MT2-selective ligands, mainly focusing on binding data on MT1 and MT2 receptor, are reviewed in detail according to their structural classes, and the relative pharmacophore, receptor binding models and the relationship between the structure of ligand and the affinity along with selectivity for receptor subtype were discussed, which may facilitate the exploration of more potent and effective MT2-selective ligands.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results